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Abstract
Background: The GABAA-α5 receptor antagonist S44819 is a promising candidate to enhance functional recovery
after acute ischemic stroke (IS). S44819 is currently evaluated in this indication; RESTORE brain study started in Dec
2016 and was completed in March 2019.
Methods/design: The study is a 3-month international, randomized, double-blind, parallel group, placebo-
controlled phase II multicentre study. Patients in 14 countries who suffered an IS leading to a moderate or severe
deficit defined by NIHSS score ranging from 7 to 20 and are aged between 18 to 85 years are included between 3
and 8 days after the stroke onset. Approximately 580 patients are to be included.
The primary objective of the study is to demonstrate the superiority of at least one of the two doses of S44819
(150 or 300 mg bid) compared to placebo on top of usual care on functional recovery measured with the modified
Rankin scale at 3 months. Comparisons between two doses of S44819 and placebo are assessed with ordinal
logistic regression evaluating the odds of shifting from one category to the next in the direction of a better
outcome at day 90. Secondary objectives include the evaluation of S44819 effects on neurological examination
using the National Institute of Health Stroke Scale total score, activities of daily living using the Barthel Index total
score, and cognitive performance using the Montreal Cognitive Assessment scale total score and Trail Making Test
times. Safety and tolerability of the two doses of S44819 will also be analyzed.
Discussion: The RESTORE BRAIN study might represent the first proof of concept study of an innovative
therapeutic approach that is primarily based on enhancing functional recovery after IS.
Trial registration: Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event, an
international, multi-centre, randomized, double-blind placebo-controlled phase II study. ClinicalTrials.gov, NCT02
877615; Eudract 2016–001005-16. Registered 24 August 2016
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Background
Post-stroke recovery relies on brain neuroplasticity [1,
2], which is compromised by the sustained hypoexcit-
ability observed in the peri-infarct cortex due to the in-
creased activity of GABAergic neurons [3].
S44819 is a potent and selective antagonist of GABAA-
α5 receptors [4] that enhances motor and cognitive re-
covery when administered chronically from day 3 after
IS in rodent models [5]. A transcranial magnetic stimu-
lation study has demonstrated in humans that S44819
reaches the human cortex and is capable of increasing
cortical and cortico-spinal excitability by reducing
GABAA receptor-mediated activity [6].
The design of a phase II clinical trial testing the effi-
cacy of two doses of S44819 on functional recovery after
acute supratentorial IS is presented.
Methods/design
Design
In accordance with the EMA’s guidance on stroke [7],
the study includes a selection period and a double-blind
treatment period of 90 days. A follow-up period of 15
days after the end of treatment allows evaluation of the
safety of patients (Fig. 1).
Patient population
Male or female patients aged 18–85 years are rando-
mised between 3 and 8 days after the stroke event based
on the following criteria: 1) acute IS confirmed by MRI
or CT; 2) NIHSS score between 7 and 20 both inclusive
[8, 9]; 3) lack of previous disability defined as an
estimated prestroke mRS score 0–1; 4) written informed
consent.
Patients are ineligible if: 1) an acute hemorrhagic
stroke or symptomatic hemorrhagic transformation or
cerebral venous thrombosis occurs; 2) the required re-
habilitation is impossible to undertake; 3) a carotid end-
arterectomy is planned within the next 3 months; 4) a
previous clinically significant condition interferes with
the study evaluation; 5) brain imaging shows a severe
microangiopathy (Fazekas grade 3 with severe small ves-
sels disease on MRI or CT scan); 6) receiving a treat-
ment that could have an impact on treatment efficacy
(i.e., interacting with GABA-A receptors) or a clinically
relevant abnormality likely to interfere with study out-
come, such as any renal or hepatic severe impairment
and any repeated QTcF prolongation. Patients who are
not able to cooperate as well as those presenting with
geographic or social factors making their study participa-
tion impossible are excluded.
Setting
The study is conducted in 92 hospital stroke centers
in 14 countries (Australia, Belgium, Brazil, Canada,
Czech Republic, France, Germany, Hungary, Italy,
Poland, South Korea, Spain, The Netherlands, United
Kingdom) that have experienced specialists in stroke
medicine (e.g., are able to perform intravenous
thrombolytic therapy, brain imaging for diagnosis). At
discharge from hospital stroke centers, patients re-
ceive rehabilitation therapy (in- or out-patient re-
habilitation) in accordance with the standard of care
Fig. 1 Treatment arms
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in each country and their clinical status. Patients are
followed by the enrolling investigators.
Randomization
The treatment is assigned at the inclusion visit by a bal-
anced, non-adaptive randomization, with stratification
by country and previous revascularization therapy status
(thrombolysis and/or endovascular therapy). Patients are
randomized into one of the three groups: S 44819 (150
mg or 300 mg twice a day) or placebo to reach about
194 patients per treatment arm. Randomization and allo-
cations are centralized by Interactive Web Response Sys-
tem (IWRS) under blind conditions for subjects,
caregivers, investigators, study-related staff, and sponsor.
The placebo is made up of hydroxypropyl methylcellu-
lose acetate succinate and different iron oxide colorants
and is an off-white to yellow powder in a sealed sachet
for oral suspension. Investigational Medicinal Product
(IMP) is provided in the form of sachets (two sachets
per intake) with an identical appearance and taste for all
treatment groups. The circumstances under which
blinding may be broken in IWRS are any serious AEs or
severe medical conditions where the knowledge of the
treatment is necessary for safety follow-up of the
patient.
The Methodology and Analysis of Clinical Data Div-
ision of I.R.I.S is responsible for designing and con-
structing the blinded randomization list.
Treatment
Study treatments are S 44819 (150 or 300 mg/bid)
and placebo. The choice of doses is mainly based on
a Transcranial Magnetic Stimulation study which has
demonstrated that S 44819—at least at doses > 100
mg—reaches the human cortex and increases cortico-
spinal excitability by reducing GABAA α5-mediated
inhibition [6].
As no validated post-acute phase treatment exists to
improve functional recovery after stroke events, no ac-
tive comparator is available. In this context, a placebo
comparator group is commonly employed and required
by the guidelines to demonstrate efficacy in controlled
clinical trials [10].
During the double-blind treatment period (D0 to
D90), S 44819 or placebo is provided in the form of sa-
chets (two in the morning and two in the evening) of
identical appearance and taste for all treatment groups.
Patients remain on the same IMP and dose throughout
the treatment period. Depending on the patient’s condi-
tion, different methods of treatment administration are
planned, e.g., with a glass of water or thickened water, if
necessary through a nasogastric tube.
Criteria for discontinuing treatment are any adverse
event according to the judgment of the investigator, any
QTcF prolongation, any severe hepatic event, any suicide
attempt, any symptomatic haemorrhagic stroke, or any
new IS. Also, consent withdrawal or any event which
could jeopardize the patient’s safety lead to treatment
discontinuation. In such a situation, the withdrawal rea-
son is reported and all examinations are expected to be
performed.
Compliance with treatment is assessed at each study
visit by deduction of the number of sachets dispensed
and returned.
Endpoints and measurements
The primary objective is to demonstrate the superiority
of at least one of the two doses of S 44819 versus pla-
cebo on functional recovery after IS based on the modi-
fied Rankin Scale (mRS) [11] measured after 90 days of
treatment. The mRS is administered at days 5, 30, 60,
and 90 and at the follow-up visit (day 105).
The secondary objectives are to assess the efficacy of
two doses of S 44819 versus placebo on stroke recovery
using the National Institute of Health Stroke Scale
(NIHSS) [12], on activities of daily living using Barthel
Index (BI) total scores [13], and on cognitive perform-
ance tests (MoCA, TMT), as well as the safety and toler-
ability of S 44819.
The NIHSS is administered at selection visit, at base-
line (day 0, inclusion), and at days 5, 30, 60, 90, and 105.
The BI is administered at days 30, 60, 90, and 105.
Cognitive performance is assessed using the Montreal
Cognitive Assessment scale (MoCA) [14] and Trail Mak-
ing Test (TMT) [15]. The MoCA (total score) and TMT
(A and B, times) results are obtained at days 30 and 90.
In order to evaluate cognitive performances when the
condition begins to stabilize, cognitive assessment is ob-
tained at 1 month and 3months to assess the course of
cognitive impairment in each stroke patient.
A visual analog scale evaluates various sub-dimensions
of the participant’s quality of life (appetite, sleep, day-
time alertness, mood, anxiety, and pain).
Safety and tolerability assessment includes adverse
event (AE) recording, vital signs, and physical examin-
ation at all visits; body weight at selection, days 30, 60,
90, and 105, BMI and ECG parameters at days 0, 5, 30,
60, 90, and 105, and different laboratory parameters at
days 0, 30, 60, 90, and 105.
Suicidal ideation and suicidal behavior is assessed
using the Columbia Suicide Severity Rating Scale (C-
SSRS) [16] and is administered at each visit from days 5
to 105.
Measurements are also performed in case of prema-
ture withdrawal.
A SPIRIT figure is shown in Fig. 2 and a SPIRIT
checklist is available in Additional file 1.
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Sample size estimates
The sample size (580 patients) was estimated based on
the mRS score at day 90, using the last observation car-
ried forward (LOCF) approach, to detect a treatment ef-
fect between at least one dose of S 44819 and
placebo in the full analysis set (FAS) using White-
head’s formula [17] for ordered categorical criteria.
To maintain the experiment-wise type I error at 5%,
the Bonferroni correction is to be applied. A drop-out
rate of 5% until D5 was considered. This sample size
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure
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should allow reaching the primary objective with a
power of 85% if the true difference is 15 points in
the cumulative proportion of patients with mRS 0–2
after 90 days of treatment and considering the follow-
ing distribution of mRS assumed for placebo after 90
days of treatment:
mRS 0 1 2 3 4 5–6
Placebo (%) 10 15 20 20 20 15
The placebo distribution was adapted from the NEST-
1 trial [18] with similar inclusion criteria concerning se-
verity (NIHSS score between 7 and 22). The results of
NEST-1 show that such a placebo distribution is a rea-
sonable estimation.
Statistical analysis
Main analysis
The primary efficacy objective is assessed in the FAS (all
patients of the RS=Randomised Set having taken at least
one dose of treatment and having at least a value for the
primary efficacy endpoint after D5) from the mRS score
at day 90. An ordinal logistic regression assesses the
odds of shifting from one category to the next on the
mRS scale. Analysis includes the fixed, categorical effects
of treatment (including the three treatment groups),
country, and previous revascularisation therapy. Missing
data are imputed with the LOCF approach. The step-
down Dunnett procedure accounts for multiplicity of
comparisons.
To assess the robustness of the primary analysis
results with regard to the method of handling missing
data, an ordinal logistic regression, including the fixed,
categorical effects of treatment, country, and previous
revascularisation therapy, is carried out in the FAS
considering the multiple imputation method. The same
analysis as the primary analysis is performed in the FAS,
including in addition the continuous fixed, covariates of
age, and baseline NIHSS score. Multiplicity is handled in
the same way as in the primary analysis.
Secondary analyses
The same analyses as for the primary analysis are
performed in patients of the per protocol set (all
completed patient data of the FAS without relevant
deviation). The difference between each S 44819 dose
and placebo is studied in the FAS at day 90 on the
dichotomized mRS scores (0–1 versus 2–6 and 0–2
versus 3–6) using a logistic regression including the
fixed, categorical effect(s) of treatment, country, and
previous revascularisation therapy. Missing data at day
90 are imputed with the LOCF approach. The step-
down Dunnett procedure is used to account for multipli-
city of comparisons.
Descriptive statistics by treatment group are provided
for all analytical approaches of the primary efficacy
endpoint in patients of the FAS. The mRS score is
described at each visit in patients of the per protocol set.
Secondary endpoints The secondary efficacy endpoints
include 1) the value of the NIHSS score at baseline and
at each post-baseline visit, 2) the value of the BI total
score at each visit, 3) the value of the MoCA total score
at each visit, and 4) the TMT times at each visit.
The difference between each S 44819 dose and
placebo is studied in the FAS at day 90 for the NIHSS
and BI scores using a Mann–Whitney test. Missing data
at day 90 are imputed with the LOCF approach.
Descriptive statistics by treatment group are provided
for the NIHSS, BI, MoCA, and TMT endpoints in
patients of the FAS.
Number of events and the number and percentage of
patients reporting at least one adverse event are
provided for serious and emergent adverse events. These
events are described according to the seriousness,
intensity, relationship, action taken regarding S 44819,
the requirement of added therapy, time from onset, and
outcome.
Vital signs, laboratory parameters, ECG parameters,
and physical examination are described in terms of value
at baseline, value at each post-baseline visit under treat-
ment, last post-baseline values under treatment, and
values at follow-up visit, as well as variations from base-
line to each post-baseline visit under treatment and to
the last post-baseline value under treatment.
For suicidal ideation score from the C-SSRS, the num-
ber and percentage of patients is assessed considering
their maximum suicidal ideation score during treatment.
Suicidal ideation score is also described at follow-up
visit. For the other outcomes, the number and percent-
age of patients that reach each outcome during treat-
ment (defined as a “yes” answer at any time during
treatment) and at follow-up visit are described.
Patient quality of Life (QoL) is scored at each visit and
descriptive statistics are reported for visual analogue scale
scores for the D0–D90 period as well as at day 105.
Statistical analysis is performed using SAS® software,
version 9.2 (Cary, NC, USA).
Data Monitoring Committee
1A Data Monitoring Committee (DMC) is responsible
for reviewing on a regular basis strictly confidential
data related to the safety of patients participating in
the study. Based on the review of the safety data, the
DMC gives written recommendations to the sponsor
about the continuation of the study per the protocol
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until the next DMC meeting, or about the
continuation of the study with modification(s) that
have no impact on the study design, or about the
premature discontinuation of the study.
Discussion
S 44819 exerts long lasting improvement of post-stroke
recovery in rodent IS models when administered from
day 3 after the ischemic insult [5] and has been shown
to increase cortical excitability by decreasing GABA-
mediated inhibition in healthy volunteers [6]. It is hy-
pothesized that S 44819 may enhance post-stroke neuro-
plasticity in patients by counteracting enhanced cortical
tonic inhibition.
Accumulating evidence suggests that there is a critical
period of increased neuroplasticity during the early post-
stroke recovery phase [3, 19] and it is crucial to initiate
therapy during this time window. In this trial, S 44819 is
administered to patients starting 3 to 8 days after stroke
onset.
The study protocol considers all ethical principles of a
placebo-controlled trial and the best standards of care. To
increase the acceptability of the present study, the prob-
ability to receive placebo is fixed at 33%. Given that S
44819 is expected to improve recovery in IS patients re-
gardless of their initial condition, a shift analysis is recom-
mended [20]. Comparisons between S 44819 and placebo
are assessed using ordinal logistic regression to assess the
odds of shifting from one category to the next.
The mRS, NIHSS, and BI scales are analyzed as
secondary efficacy scales; they are recommended by
EMA guidelines to assess the efficacy of medicinal
products for treating acute stroke [7].
S 44819 does not bind to benzodiazepine sites or to
GABAA receptors containing α1, α2, and α3 subunits [4]
and presumably does not cause adverse effects triggered
by these subunits; so far, no safety concern has arisen
from the phase I and the on-going phase II study.
Conclusion
This trial may provide the first proof of concept for an
innovative therapeutic approach based on the
enhancement of functional recovery after IS.
Trial status
Protocol version 7, 23/07/2018. The study started in Dec
2016 and was completed in March 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4072-2.
Additional file 1. SPIRIT 2013 checklist: Recommended items to address
in a clinical trial protocol and related documents.
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